Chief Medical and Scientific Officer
Rain Oncology
Newark, California, United States
Robert Doebele is Co-Founder, Chief Medical and Scientific Officer of Rain Oncology where he directs scientific and clinical strategy for novel precision oncology drugs. Dr. Doebele’s background is as a physician-scientist with clinical and research expertise in targeted therapies and precision oncology strategies. Dr. Doebele earned his degree in Molecular Biology from Princeton University and his MD/PhD in Immunology from the University of Pennsylvania School of Medicine. Prior to cofounding Rain Oncology, Dr. Doebele’s research at the University of Colorado launched the NTRK field by demonstrating that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of larotrectinib (Loxo) and entrectinib (Ignyta).
Disclosure information not submitted.
Thursday, November 2, 2023
4:00 PM – 5:30 PM
